Literature DB >> 13322909

Symposium on the treatment of cerebrovascular disease; stellate ganglion block in the treatment of cerebrovascular disease.

R C WALSH.   

Abstract

Entities:  

Keywords:  ANESTHESIA, REGIONAL; CEREBRAL EMBOLISM AND THROMBOSIS/complications; HEMIPLEGIA/etiology and pathogenesis

Mesh:

Year:  1956        PMID: 13322909      PMCID: PMC1888847     

Source DB:  PubMed          Journal:  Proc R Soc Med        ISSN: 0035-9157


× No keyword cloud information.
  11 in total

1.  The prognosis and management of subarachnoid haemorrhage.

Authors:  J N WALTON
Journal:  Can Med Assoc J       Date:  1955-02-01       Impact factor: 8.262

2.  The circle of Willis.

Authors:  C SYMONDS
Journal:  Br Med J       Date:  1955-01-15

3.  The prognosis and role of surgery in spontaneous intracranial haemorrhage.

Authors:  J M SMALL; J M HOLMES; R C CONNOLLY
Journal:  Br Med J       Date:  1953-11-14

4.  The surgical treatment of intracerebral haemorrhage.

Authors:  D BECK
Journal:  Arch Middx Hosp       Date:  1953-07

5.  Surgical Treatment of Spontaneous Subarachnoid Haemorrhage.

Authors:  M A Falconer
Journal:  Br Med J       Date:  1950-04-08

6.  Stellate ganglion block in general practice.

Authors:  R C WALSH
Journal:  Br Med J       Date:  1954-09-18

7.  The distribution of blood to the brain.

Authors:  D A McDONALD; J M POTTER
Journal:  J Physiol       Date:  1951-07       Impact factor: 5.182

8.  The cervical sympathetic ganglia: an anatomical study of 100 cervicothoracic dissections.

Authors:  D W JAMIESON; D B SMITH; J B ANSON
Journal:  Q Bull Northwest Univ Med Sch       Date:  1952

9.  The pathology, diagnosis and treatment of intracranial saccular aneurysms.

Authors:  G NORLEN; M FALCONER; G JEFFERSON; R JOHNSON
Journal:  Proc R Soc Med       Date:  1952-05

10.  The pathogenesis of hypertensive encephalopathy and its relation to the malignant phase of hypertension; experimental evidence from the hypertensive rat.

Authors:  F B BYROM
Journal:  Lancet       Date:  1954-07-31       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.